Therapy

HSS Receives Betty J. Cleckley Minority Issues Research Award from American Public Health Association

Magnet, Hospital, HSS, Infection, Betty, Central New York Regional Market, Research, American Public Health Association, Hospital for Special Surgery, Rheumatology, Manuscript, Elective surgery, Long Island, U.S. News & World Report, Data collection, Anxiety, Organization, 2009 Davis Cup, Ageing, Physician, Public health, APHA, Focus group, Multimedia, American Nurses Credentialing Center, Weill Cornell Medicine, Program, Laboratory, Health, News, Nursing, McGrath, Therapy, Community education, Department, Education, The Hospital, Medicine
Monday, October 25, 2021 - 11:00pm

NEW YORK, Oct. 25, 2021 /PRNewswire/ --The Department of Community Education & Outreach at Hospital for Special Surgery (HSS) has received the Betty J. Cleckley Minority Issues Research Award at the American Public Health Association (APHA) annual meeting.

Key Points: 
  • NEW YORK, Oct. 25, 2021 /PRNewswire/ --The Department of Community Education & Outreach at Hospital for Special Surgery (HSS) has received the Betty J. Cleckley Minority Issues Research Award at the American Public Health Association (APHA) annual meeting.
  • The award recognizes individuals in aging and public health research who have made a significant impact on the lives of older people who are members of minority groups, according to the APHA.
  • The organization notes that minimizing health disparities and improving access to health and long-term care services are important issues for minority populations in the United States.
  • HSS is the award recipient for its manuscript titled, "Utilizing Alternative Strategies to Keep Underserved and Vulnerable Communities Socially Connected."

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General counsel, Nasdaq, Therapy, Employment, Microcystic lymphatic malformation, GLOBE, Financial compensation, Cancer, Degenerative disease, Professional Football Compensation Committee, Protaras, Pharmaceutical industry
Monday, October 25, 2021 - 9:45pm

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.

Key Points: 
  • NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.
  • The Compensation Committee of Protaras Board of Directors approved the awards as an inducement material to Ms. Grendells employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • For more information, visit www.protaratx.com

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021

Fibrosis, 2021 Essex County Council election, AASLD, SAN, LinkedIn, PD, Association, Hypertriglyceridemia, Institute of Liver and Biliary Sciences, Safe harbor, Triglyceride, NAFLD, Steatosis, Patient, American Association for the Study of Liver Diseases, Private Securities Litigation Reform Act, SEC, POC, Disclosure, Trial of the century, COVID-19, Inflammation, The O.C., Pharmacokinetics, Health, Fatty liver disease, American Association, Therapy, NASH, Half-life, GLOBE, Population, FGF21, Diabetes, Pharmaceutical industry
Monday, October 25, 2021 - 9:05pm

The presentations will also be available on the 89bio website after the meeting.

Key Points: 
  • The presentations will also be available on the 89bio website after the meeting.
  • FGF21 is an endogenous hormone that modulates important drivers of NASH including glycemic control, steatosis, inflammation and fibrosis.
  • 89bio has advanced BIO89-100 into the Phase 2b ENLIVEN trial in NASH, which is now ongoing.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

Biology, Patient, Therapy, NASDAQ, GLOBE, Disease, Webcast, Pharmaceutical industry
Monday, October 25, 2021 - 9:05pm

The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .

Key Points: 
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

OPY Acquisition Corp. I Announces Launch of $100 Million Initial Public Offering

Professional Services, Medical Supplies, Health, Medical Devices, Finance, General Health, Biotechnology, Oppenheimer, IPO, Industry, Security (finance), U.S. Securities and Exchange Commission, SPAC, Broad Street, Telephone, SEC, Forward-looking statement, Risk, Company, Nasdaq, Exchange, Prospectus, Acquisition, Therapy, Sale
Monday, October 25, 2021 - 9:01pm

Each whole warrant will entitle the holder thereof to purchase one share of Class A common stock at $11.50 per share.

Key Points: 
  • Each whole warrant will entitle the holder thereof to purchase one share of Class A common stock at $11.50 per share.
  • Oppenheimer & Co. Inc. and Lake Street Capital Markets are acting as joint book-running managers for the offering.
  • This press release contains statements that constitute forward-looking statements, including with respect to the Companys initial public offering (IPO) and search for an initial business combination.
  • Forward-looking statements are subject to numerous conditions, many of which are beyond the control of OPY Acquisition Corp.

Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET

Judgement, Research, Securities Act of 1933, ADC, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, FDA, Machine learning, SEC, Probability, Risk, Annual report, Marketing, Company, A.I, Intention, COVID-19, Multimedia, Lantern, Drug Quality and Security Act, Therapy, Securities Exchange Act of 1934, Fine chemical, Pharmaceutical industry
Monday, October 25, 2021 - 9:57pm

DALLAS, Oct. 25, 2021 /PRNewswire/ --Lantern Pharma(NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")

Key Points: 
  • DALLAS, Oct. 25, 2021 /PRNewswire/ --Lantern Pharma(NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")
  • Management intends to discuss the financial and operating results for the third quarter ended September 30, 2021 and provide guidance on upcoming milestones.
  • The call will be led by Panna Sharma, President and Chief Executive Officer of Lantern Pharma.
  • Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs.

Statement from Akebia Therapeutics Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services

Cough, BIO, IV, Iron, Organization, Hyperphosphatemia, HHS, American Kidney Fund, Nausea, Dialysis, TSAT, Pregnancy, Lactation, Birth, United States Court of Appeals for the First Circuit, Transferrin, Therapy, Centers for Medicare & Medicaid Services, Risk, CMS, National Kidney Foundation, Gestational diabetes, Miscarriage, Constipation, Hyperkalemia, Overdose, Abdominal pain, Goal, Milk, Medicare Part D, Biotechnology Innovation Organization, Infant, Office of Inspector General, U.S. Department of Health and Human Services, Center, Chronic kidney disease, Medicare, Accidental, CKD, List, Patient, Health equity, FDA, Congress, Time, Vomiting, Adult, IDA, Nephrology, Kidney disease, Pharmaceutical industry, Health insurance, Vaccine
Monday, October 25, 2021 - 9:39pm

We also asked the federal district courttoissue an injunction to immediately restorecoverageforAuryxiawhen used forIDA while the lawsuit was pending.

Key Points: 
  • We also asked the federal district courttoissue an injunction to immediately restorecoverageforAuryxiawhen used forIDA while the lawsuit was pending.
  • Unfortunately, thefederal district courtdeniedour motionforapreliminaryinjunctionand the U.S. Court of Appeals for the First Circuit affirmed the district court's decision.
  • All eligible patients deserve access to, and Medicare coverage for, critical, innovative therapies such as Auryxia for chronic kidney disease.
  • However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation.

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

808, ACTH, Research, Securities Act of 1933, SAN, State Street, Annual report, SVB Leerink, The Women on the 6th Floor, Security (finance), U.S. Securities and Exchange Commission, Drug discovery, Congenital hyperinsulinism, Telephone, Cantor, Equity capital markets, SEC, Exercise, Degenerative disease, Wilms' tumor, Congenital adrenal hyperplasia, Park, Attention, Form 10-K, Acromegaly, Nasdaq, Prospectus, Therapy, GLOBE, Securities Exchange Act of 1934, Sale, Pharmaceutical industry
Monday, October 25, 2021 - 9:01pm

The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $172.5 million.

Key Points: 
  • The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $172.5 million.
  • SVB Leerink, Evercore ISI and Cantor acted as joint bookrunning managers for the offering.
  • H.C. Wainwright & Co. acted as lead manager and JonesTrading acted as co-manager for the offering.
  • Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment ofcarcinoid syndromeassociated with neuroendocrine tumors.

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Science, Chairperson, Medication, Inflammation, Molecular medicine, Scripps Research, Cancer, Neoplasm, Microbiology, Immunotherapy, Patient, Society, Cecil H. Green Library, Stanford University, Immunology, Therapy, SITC, Department, Pharmaceutical industry
Monday, October 25, 2021 - 9:00pm

Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the companys lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Key Points: 
  • Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the companys lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.
  • Palleons poster highlights recent preclinical data from in vitro and in vivo studies of the companys most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase).
  • E-602 is part of the companys novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.
  • These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology.

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, RNA transfection, Duke–NUS Medical School, Takeda Pharmaceutical Company, Cystic Fibrosis Foundation, Hepatitis B virus, Glycogen storage disease type III, LinkedIn, Vaccine, III, Cystic fibrosis, ARCT, Messenger RNA, Twitter, Janssen Pharmaceuticals, RNA, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, Patent, OTC, COVID-19, Diversified Specialty Institute Holdings, Inc., Nasdaq, Fatty liver disease, NASH, MicroRNA, Therapy, CureVac, Gene editing, DNA, Baking
Monday, October 25, 2021 - 9:00pm

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005719/en/